MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-026-08173-x

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2026

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.

Giunta Emilio Francesco, Marini Irene, Grassi Ilaria, Nicolini Silvia, Foca Flavia, Celli Monica, Caroli Paola, Sarnelli Anna, Brighi Nicole, Schepisi Giuseppe, Monti Manuela, De Giorgi Ugo, Lolli Cristian, Sansovini Maddalena

СтатьяПеревод в очереди

Аннотация

PURPOSE: 177Lu-PSMA is currently approved for metastatic castration-resistant prostate cancer (mCRPC). However, only a subset of eligible patients derives a meaningful clinical benefit from treatment. To date, there is a lack of validated biomarkers that could help find the best candidates for this radioligand therapy (RLT).

METHODS

142 patients undergoing 177Lu-PSMA therapy were enrolled in a biological observational prospective study, with blood samples collected at baseline for analysis. Clinical characteristics and routinely available laboratory biomarkers - including hemoglobin, alkaline phosphatase, prostate-specific antigen (PSA), and carcinoembryonic antigen (CEA) - were evaluated by uni- and multivariable Cox regression analyses for their association with progression-free survival (PFS) and overall survival (OS).

RESULTS

At a median follow-up of 44.0 months, median PFS and OS were 7.0 and 16.8 months, respectively. Elevated baseline CEA was independently associated with shorter PFS (p = 0.026) and OS (p = 0.003). Moreover, combining CEA with PSA improved prognostic discrimination compared with PSA alone.

CONCLUSION

Baseline CEA was independently associated with shorter PFS and OS, supporting its role as a promising prognostic biomarker for patients with mCRPC undergoing 177Lu-PSMA therapy. Further studies are warranted to validate its prognostic value and determine whether it also has predictive utility.

Для цитирования: Giunta Emilio Francesco, Marini Irene, Grassi Ilaria, Nicolini Silvia, Foca Flavia, Celli Monica, Caroli Paola, Sarnelli Anna, Brighi Nicole, Schepisi Giuseppe, Monti Manuela, De Giorgi Ugo, Lolli Cristian, Sansovini Maddalena. Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.. European journal of nuclear medicine and molecular imaging. 2026. DOI: 10.1007/s00259-026-08173-x.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.